Charles River Labs Stock - Morgan Stanley upgrade shifts sentiment
19.06.2026 - 17:35:33 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 17:33 CET. Details in the imprint.
Charles River Labs (US1591881009) draws renewed attention after Morgan Stanley upgraded the stock to Overweight and raised its price target to $220 from $185, according to a Morgan Stanley note summarized by TheStreet on 06/17/2026. TheStreet report on the Morgan Stanley rating change.
All news and analysis on Charles River Labs stock
Keep track of current ratings, earnings dates and regulatory filings for Charles River Labs stock and how they compare with the wider life-sciences services sector.
Morgan Stanley turns more positive
Morgan Stanley shifted its stance on Charles River Labs to Overweight from Equal-weight and lifted its price target to $220, a roughly 19% premium to the recent close around $185, according to TheStreet. TheStreet summary of the Morgan Stanley call The move was paired with a downgrade of IQVIA Holdings to Equal-weight.
The bank argued that key drug research outsourcers face diverging trajectories as biopharma clients adjust R&D budgets. Morgan Stanley sees Charles River as better positioned for a recovery in preclinical and early development demand than some peers, even after a period of muted sentiment in the group. Mexc News recap of Morgan Stanley's sector view
How the stock stacks up this week
In the latest session on 06/18/2026, Charles River Labs shares closed near $185 on Nasdaq, leaving the company with a market capitalization around $8.9 billion, according to recent quote data. TradingKey data on Charles River Labs That puts the stock below its 52-week high but above the lows seen during the sector's softer phase.
On balance, the Morgan Stanley call arrives at the end of a week where life-sciences service providers have had to contend with shifting expectations around biotech funding and large-pharma outsourcing. The upgrade may help narrow the valuation gap versus some contract research and lab peers if investors grow more confident in the revenue trajectory.
The business behind the stock
Charles River Labs generates most of its revenue by providing preclinical and early-stage clinical research services, including safety assessment, discovery and pharmacology, as well as supplying research models and related services to pharmaceutical and biotech companies worldwide. The company also offers cell and gene therapy testing and manufacturing support.
Where the stock trades today
Charles River Labs (US1591881009) shares trade on Nasdaq at about $185.00 as of 06/18/2026, 16:00 ET.
Key facts on Charles River Labs stock
- Company: Charles River Laboratories International Inc.
- ISIN: US1591881009
- Ticker: CRL
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 185.00 USD
- Market cap: 8,910,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care - Life Sciences Tools & Services
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
